Recent Analysts’ Ratings Changes for Neumora Therapeutics (NMRA)

A number of research firms have changed their ratings and price targets for Neumora Therapeutics (NASDAQ: NMRA):

• 1/6/2025 – Neumora Therapeutics had its price target lowered by analysts at Bank of America Co. from $22.00 to $7.00. They now have a “buy” rating on the stock.
• 1/3/2025 – Neumora Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
• 1/2/2025 – Neumora Therapeutics was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $4.00 price target on the stock, down previously from $29.00.
• 1/2/2025 – Neumora Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
• 12/16/2024 – Neumora Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
• 11/22/2024 – Neumora Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $29.00 price target on the stock.
• 11/13/2024 – Neumora Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
• 11/13/2024 – Neumora Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.

Neumora Therapeutics Trading Down 8.1 %

NASDAQ NMRA opened at $2.37 on Thursday. Neumora Therapeutics, Inc. has a 12 month low of $1.83 and a 12 month high of $21.00. The stock has a market cap of $382.90 million, a PE ratio of -1.27 and a beta of 2.71. The stock’s 50 day moving average is $9.90 and its 200 day moving average is $11.35.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the previous year, the firm earned ($1.14) EPS. On average, analysts forecast that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Insider Activity

In related news, Director Matthew K. Fust sold 14,049 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the transaction, the director now directly owns 20,100 shares of the company’s stock, valued at approximately $342,303. This represents a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NMRA. Geode Capital Management LLC increased its position in Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares during the last quarter. Barclays PLC raised its position in shares of Neumora Therapeutics by 352.9% during the 3rd quarter. Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 after buying an additional 100,678 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Neumora Therapeutics by 139.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after acquiring an additional 406,891 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Neumora Therapeutics in the third quarter worth about $1,097,000. Finally, Callan Capital LLC increased its stake in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after acquiring an additional 456,207 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.